Enhabit, Inc.

Operator, good morning, everyone. Thank you for joining Inhabit Home Health and Hospice's fourth quarter 2023 earnings conference call. With me on the call today is Barb Jacobsmeyer, President and Chief Executive Officer. Before we begin, if you do not already have a copy, the fourth quarter earnings release, supplemental information, and related form 8K filed with the SEC are available on our website at investors.ehab.com. On page two of the supplemental information, you will find the safe harbor statement, which are also set forth on the last page of the earnings release. During the call, we will make forward-looking statements which are subject to risk and uncertainty, many of which are beyond our control. Certain risks and uncertainties that could cause actual results to differ materially from our projections, estimates, and expectations are discussed in our SEC filing, including our annual report on Form 10-K

which are available on our website.

You are cautioned not to place undue reliance on the estimates, projections, guidance, and other forward-looking information presented, which are based on current estimates of future events and speak only as of today. We do not undertake a duty to update these forward-looking statements. Our supplemental information and discussion on this call will include certain non-GAAP financial measures. For such measures, Reconciliation to the most directly comparable gap measure is available at the end of the supplemental information and the earnings release. With that, I'll turn the call over to Barb.

Thanks, Chrissy. Good morning, and thanks for joining us. Persistent focus on our company strategies drove our positive fourth quarter results. Payer innovation success, including the execution of another new national contract, continued success with our people strategy, And strong performance and quality outcomes are but a few of our high points for the end of 2023 and our start to 2024. I cannot thank our employees enough for the high quality care they provide to our patients every day. Our strongest factor in negotiating with payers and conveners and in creating strong referral relationships remains our 30-day hospital readmission rate that is 20.5% better than the national average. This quality is a solution to the challenge of rising healthcare costs and helping payers manage their MLRs. Helping to control emergency room visits, hospitalizations, and readmissions results in higher patient and family satisfaction and control of healthcare dollars. Significant dollars are also spent at the end of people's lives. High quality hospice care, and in particular, Consistent and attentive clinician visits during the last days of life are critical in preventing revocations and unnecessary hospitalizations because of the benefit it provides our patients and their families. We are proud that our team provides hospice visits in the last days of life 53.2% better than the national average. We anticipate our home health and hospice quality will continue to drive our future growth as well as employee retention. Now let's talk about some of our key 2024 focus areas and how the fourth quarter set us up for success. With our traditional Medicare mix of home health revenue now in line with peers, we expect the continued decline in our traditional Medicare volumes to slow at a rate consistent with the industry in 2024. Episodic admissions are beginning to stabilize as our sequential episodic admissions were down only 0.8% in the fourth quarter compared to the third quarter. With our strong quality metrics and our increased list of the payers we can accept, we expect an increase in referrals as we improve our status as a preferred provider. Our payer innovation team continues to succeed in demonstrating our value proposition to Medicare Advantage payers and has set us up for success with these payers in 2024. We had another strong quarter negotiating a total of 11 new agreements, with eight of those negotiated at episodic rates. Specifically, we are extremely excited to announce a new national agreement that became effective January 1, 2024. This new national agreement is an advanced episodic model that allows us to prioritize access to home care for patients discharged from institutional settings. Said in another way, it aligns our incentives with the payer's needs for member access to skilled home care for a successful transition to home following an institutional admission. This contract allows us to further increase our focus on moving volumes away from the lower paying agreements that do not recognize the value of our high quality outcomes. Since the inception of the payer innovation team in the summer of 2022, we have successfully negotiated 59 new agreements. Over two-thirds of those are at episodic rates. Our home health business development and branch operations teams continue to be successful in moving volume to our payer innovation agreements. In the fourth quarter, approximately 25% of our non-episodic visits were in new payer innovation contracts, That is up from 5% in Quarter 1, 2023. We are confident in our ability to make continued improvement in Medicare Advantage pricing and in the shift of our Medicare Advantage admissions to these improved contracts. With an advanced episodic model added to our payer contracts versus a traditional episodic structure, we will now update how we report our payer groups in 2024, separating traditional Medicare from all other episodic contracts. Our rollout of metallogic pulse to all of our branches was complete by the end of quarter three. Our visits per episode in quarter four was flat year over year at 14.3 and down sequentially from quarter three to 14.9. We continue to work with our leaders on how to best use this tool for clinical resource management based on our patient's acuity and complexities. In regards to hospice, moving to the case management model has helped us recruit and retain our hospice staff, resulting in the elimination of all contract nursing and eliminating staffing capacity constraints. The sales team can now focus on further referral source development. We continually analyze our hospice business in an effort to increase efficiency in the referral to admission process and improve our ability to respond quickly to our referral sources. Recently, we reallocated certain hospice resources to form centralized admission departments with a sole focus on those efforts. We complement our organic growth strategy with our de novo strategy. This allows us to enter a new market with low capital costs. The main investment is in staffing as we hire the clinical team to build the patient census to obtain our licensing survey. We added one home health and one hospice de novo location in quarter four, bringing our 2023 total to eight. Two additional locations are complete with the necessary preparation steps and are awaiting regulatory approval. We expect to finalize these two from 2023 and open another 10 de novo locations in 2024. Our operational and sales teams are focused on ramping up referral and admissions growth in the de novo locations opened in 2023. Continued progress with our people strategy remains a priority, and we believe we're winning the battle for labor. During the fourth quarter, our full-time nursing candidate pool increased 21.5% year over year and resulted in the addition of 119 net new full-time nurses. Given our strong nursing hires in 2023, we eliminated all hospice nursing contract labor by the end of quarter three and all home health nursing contract labor by the end of the year. Our focus in 2024 will be on employee engagement so we can continue to improve retention. In particular, we are focused on our clinicians' satisfaction with their schedules. Given our success with nursing hires, we are now able to turn some talent acquisition resources to recruiting additional therapists as our improved nursing workforce is allowing us to grow and add therapy team members. Before I turn it over to Christy, I want to remind everyone that the purpose of today's call is to discuss our financial and operational results and outlook. The board, with the assistance of our advisors, is being comprehensive in its assessment of strategic alternatives, and discussions with interested parties are ongoing. We are in the later stages of our strategic review but don't intend to disclose developments unless and until we determine further disclosure is appropriate or necessary. We will not be commenting beyond that, and so we ask you to keep your questions focused on our business and our results. In summary, our success in our payer strategy, in our ongoing payer innovation contracting, in our people strategy, in hospice growth strategies, and our de novos are examples of our continuing investment for the future, to meet the growing need of home health and hospice services. I will now turn it over to Chrissy to further discuss the quarter's results and 2024 guidance.

Thanks, Barb. Consolidated net revenue was $260.6 million for the fourth quarter, down $2.6 million or 1% year over year. Adjusted EBITDA was $25.2 million, down $5.1 million or 16.8% year over year. We estimate the continued shift to more non-episodic payers in home health decreased revenue and adjusted EBITDA approximately 8 million year-over-year, net of the impact from improved pricing of payer innovation contracts. In our home health segment, total admissions growth of 3.9% year-over-year was driven by 34.2% growth in non-episodic admissions. Our non-episodic visits grew to approximately 33% of our total home health visits in the quarter. While we are making significant progress demonstrating our value proposition to payers as we negotiate new agreements with improved rates and are successfully shifting Medicare Advantage volumes into our payer innovation agreements, the revenue and adjusted EBITDOT impact from this volume shift has not been enough to overcome the financial impact from the erosion of Medicare fee-for-service volumes. Our home health team successfully managed cost of services, resulting in cost per visit flat year over year as the reduction in nursing contract labor offset the impact of merit market increases. For full year 2023 compared to 2022, cost per visit increased approximately 2%. That's less than the 3% average merit market increase for the year, thus demonstrating our ability to control costs through productivity and optimization of staff. In our hospice segment, revenue increased 3.7 million or 7.8% year over year, primarily due to an increase in revenue per day that resulted from changes in our estimated recoverability of net service revenue in the fourth quarter of 2022 and increased Medicare reimbursement rates that went into effect on October 1st of 2023. Admissions decreased 1.5% year over year, while average daily census decreased 4.3% year over year. Sequentially, our average daily census increased 1.3% over the third quarter. Adjusted EBITDA increased 6.1 million year over year, primarily due to the increase in revenue per day, and a reduction in general and administrative costs for the segment. Cost per day improved sequentially to $76 after stabilizing at $77 for the prior three quarters as the elimination of nursing contract labor and increased census helped gain leverage against the fixed costs associated with the case management staffing model. General and administrative expenses decreased $2.1 million year-over-year primarily due to changes in back office staffing needs as a result of implementation of the case management staffing model. Our home office general and administrative expenses increased 4.3 million year-over-year to 10.3% of consolidated revenue, primarily due to a declining revenue base, investments in information technology and talent acquisition, and annual merit increases. Our standalone company cost in 2023 approximated $23 million, which is less than the $26 to $28 million original estimate at the spend date. At this time, we have transitioned all services from Encompass Health except for our PeopleSoft financial and HR systems, and we expect to complete the transition of those services by the end of Q1 2024. Let's transition now to the balance sheet. Information on our debt and liquidity metrics is included on page 17 of the supplemental slides. We ended 2023 with a leverage ratio of 5.4 times, well within our covenant maximum of 6.75 times. We have available liquidity of approximately $61 million, including approximately $27 million of cash on hand. We believe this is adequate to support our operations, including our de novo strategy. We generated approximately $59 million of free cash flow during 2023, which equates to a free cash flow conversion rate of approximately 60%. Let's now turn to 2024. Our 2024 guidance and related guidance considerations can be found on pages 19 and 20 of the supplemental slides that accompanied our earnings release. Our 2024 guidance range for net service revenue is $1,076,000,000 to $1,102,000,000, with adjusted EBITDA in a range of $98,000,000 to $110,000,000. Within our home health segment, and as Barb mentioned in her remarks, we are focused on achieving growth through the stabilization of Medicare as a percent of total home health revenue, continued progress with our payer innovation strategy, and increased utilization of our clinical resources. We expect our Medicare pricing to increase approximately 1.2% in 2024 based on the home health final rule, and we expect our Medicare Advantage pricing to improve based on the success of our payer innovation team, including a full year of impact from the national agreement that became effective May 1, 2023, and the additional benefit of the new national agreement that became effective on January 1st of this year. For volumes, we expect the success we've had with our payer innovation team and our recruitment and retention of clinical staff to drive volume growth. With our traditional Medicare mix of home health revenue now in line with our peers, we expect the continued decline in our traditional Medicare volumes to slow to a more industry-like rate in 2024. And the new episodic payer innovation contract will provide an avenue of growth to offset some of the continued erosion of traditional Medicare. For our hospice segment, we are focused on growing census, which will also allow us to gain operating leverage against the fixed cost structure associated with the case management staffing model. For pricing, we expect our reimbursement rate will increase approximately 2.9% for the first three quarters of the year based on the hospice final rule effective October 1, 2023. For volume, we are clinically staffed to grow, and we are working with our talent acquisition team to further build our business development team for growth. On the cost side of the equation, we face two primary headwinds in 2024, wage inflation and increased costs associated with durable medical equipment. A 3% average merit and market increase results in an approximate 10 million net headwind for our company year over year. This represents the impact of wage inflation above the net reimbursement rate increases we receive from Medicare in both segments. In our home health segment, we believe we can partially offset wage inflation through productivity and optimization improvements, and currently believe our cost per visit will increase between 2% and 3% year over year. In our hospice segment, we estimate our cost per day will increase 2% to 4%. This increase is primarily due to service issues we encountered with our durable medical equipment provider in the fourth quarter of 2023. To avoid disruption to our patients and to ensure they receive the equipment they need, We made alternative arrangements in the affected markets. We estimate these new arrangements will result in an approximate $2 million of additional costs associated with durable medical equipment year-over-year. We expect patient volumes to increase without the need to hire a significant number of additional staff, resulting in operating leverage against the fixed costs associated with our case management staffing model. We expect our home office costs to stay relatively flat at the percent of consolidated revenue as merit increases and increased incentive compensation year over year are partially offset by the implementation of cost structure and other savings in 2023. As we've noted previously, our greatest challenge in forecasting relates to the shift of Medicare eligibles into Medicare Advantage and forecasting not only the mix of traditional Medicare admissions versus Medicare Advantage admissions, but also forecasting the shift of Medicare Advantage admissions into our payer innovation contracts. With this in mind, the difference between the low and high end of our guidance range primarily is dependent upon our payer mix. We expect to generate $36 to $62 million of free cash flow in 2024, as shown on page 21 of the supplemental slides that accompanied our earnings release, Free cash flow in 2024 will be impacted by our return to cash income tax payments, which represents a $12 to $14 million swing in uses of free cash flow year over year. In addition, free cash flow generation will be dependent on the timing of working capital, specifically accounts receivable.

With that, I'll ask the operator to open the lines for Q&A.

The floor is now open for your questions. To ask a question at this time, simply press star followed by the number one on your telephone keypad. We ask that you please limit yourself to one question and one follow-up question and re-queue if necessary. We'll now take a moment to compile our roster.

Our first question comes from the line of Brian Tanklett with Jefferies.

Please go ahead.

Hey, good morning and congrats on the quarter. I guess maybe, Barb, my first question, you know, you announced that national episodic contract and sounds like you're gaining traction with expanding or shifting the contracting strategy a little bit here. So just curious, number one, how are you thinking about the remaining opportunity there and what it would take to ramp that business up or that relationship up? And then maybe broadly speaking, how are you thinking about you know, how the pressures on Medicare Advantage plans are translating to you guys, and how does that impact your ability to negotiate or renegotiate your biggest Medicare Advantage relationship? Thank you.

Sure. Well, I think the ability to particularly ramp up with the new national agreement is strong. It's been good that we have always had that care transition coordinators that are inside a facility, So they actually can help us really ramp up quickly in being able to accept this payer, particularly from these institutional settings. So I think there's already the ability and the staff there to take advantage of that. I do think actually some of the challenges that the payers are facing almost work to our benefit as we're sitting at the table, particularly because of our high quality outcomes. I think if they're really looking to control those high-cost areas like hospitalizations and emergency room visits and things like that, we can help with that. But a provider has to have the high quality to be able to help with it. So it really has given us, I think, an advantage sitting at the table with these payers.

And then maybe, Chrissy, my follow-up, just as I think about guidance, right? So I'm just curious what your assumptions are in terms of – I know you said you're still expecting – payer mix shifting there, but how should we be thinking about, you know, the moving pieces on payer mix shift, maybe a little bit on wage inflation. I know you talked a little bit about cost per visit, but what are you seeing there? And then the other area would be, like, what does the recruitment pipeline look like for both nurses and therapists? Thanks.

Yeah, so I'll take kind of the guidance part of that and then turn it back to Barb for the recruitment and retention aspect of the questions. When I think about, you know, 2024 and guidance and kind of bridging 2023 to 2024, I'm really focused on the expected increase due to increased reimbursement rates in both segments, volume growth, efficiency improvement in our cost per visit and cost per day. And then some of that will be partially offset by wage inflation, that new DME contract that I just talked about, as well as some of that payer mix shift. Again, Brian, we're not expecting what I've historically referred to as the inhabit cliff. Remember that we've now entered that zone where our Medicare fee-for-service and Medicare Advantage mix is very similar to our peers. So we're expecting a more industry-like shift. We're not saying that Medicare is not going to continue to decline. They continue to choose, Medicare-eligible continue to choose Medicare Advantage plans. But we're saying we shouldn't have those same double-digit declines that you've seen for us because we made that shift over 12 to 18 months, whereas the peer group made it over six to, you know, seven to eight years. So we think that we've kind of, again, normalized ourselves into the peer group now. And so that, you know, the 30 million of payer mix impact that we saw in 2023, we don't expect to recur at that same level given where we are with our volumes in the payer mix. as well as just the improved rates that we're getting. And I think it's also important, Brian, to remember that we're starting 2024 with two national contracts. We weren't in that position at the beginning of 2023. We'll have the full benefit from the national agreement that became effective May 1 of 2023. And then, of course, the one that we announced last night that became effective January 1. So we feel we're in a much better position.

And then on your question, Brian, on labor, it was good to see quarter four tends to be a slower quarter on labor. Just, you know, folks just don't look to switch over the holidays. So we were pleased to see year over year that our applicant pool was up over 21%. So that was really good to see. And then again, we had another successful quarter with those full-time net new hires.

Awesome. Thank you, guys.

Thank you.

Our next question comes from a line of Jason Casoria. with Citigroup. Please go ahead.

Great. Thanks. Good morning. Maybe just a follow-up on Brian's question. Just any other color or consideration for us as we think about earnings cadence, right? You discussed fee-for-service kind of volumes kind of returning closer to industry norms, but I guess, you know, are you at the position kind of exiting 23 into 24 where that should develop kind of in line with that expectation, or do you think that, you know, you're going to still see outsized kind of moderation in that context? Yeah, just so anything else on the earnings cadence would be helpful to start. Thanks.

Sure, Jason. So we expect what I would call a moderate adjusted EBITDA bill throughout the year. You know, I think when we attended your conference last spring, we talked about a steep, you know, ramp in 2023. We're not really expecting that in 2024. Again, it's more of a moderate adjusted EBITDA bill throughout the year. You know, Q1 and Q4 tend to have, you know, higher volumes a little bit. I think one of the things that we're excited about in 2024 is given the success we've had with the recruitment and retention of our clinical staff, when you have more staff, you're able to manage through some of those summer anomalies around, you know, paid time off and vacations and such. So we expect to be able to manage those labor needs in Q2 and Q3 around PDO, just via increased staff and productivity. And then, of course, there will be a slight ramp of some of these new Medicare Advantage contracts, especially the new one that came into effect January 1.

Okay, great. Thank you. That's helpful. And I guess, you know, thinking about the 59 agreements you signed, right, and the 25% of your non-episodic visits, Do you think, maybe just building on your comments, Barbara, just do you think perhaps you're in a strong position to really balk against taking volumes from these lower paying contracts without sacrificing the volume density within your markets? Or how should we think about that balance between generating volume density against the reimbursement dynamics within your overall book? And then Just really quickly on a follow-up, on the hospice cost per day, can you give us a sense on what that would have been otherwise if it wasn't for this DME issue, just for us to get a sense? Thanks.

Sure. On the volume as it relates to the contracts that we've signed, I do think that there's an ability to grow the volume. Particularly the regional contracts we've signed has really been based on feedback from the field on, which thing could make a meaningful difference for them with their referral sources. I also think an opportunity for us now, you know, if you think back to last year this time, we had a really short list to bring into referral sources on the payers we could take. And frankly, it was, you know, what we hear from our referral sources is we need to have a partner that can really help us take almost all of our patients, not just one or two particular kinds. And so I think we're entering referrals versus today very differently with a much longer list, and that should help us to be able to frankly grow all volumes, but truly focused on those in the payer innovation contract and fee-for-service Medicare.

And on your question regarding the hospice cost per day, I think what you're asking me is the 2024 number because this new DMA contract was really a Q1 2024 effective date. And so I think it's fair to say, Jason, that if it weren't for this durable medical equipment agreement that we had to sign, that instead of our cost per day guidance consideration being 2% to 4%, I think it would have been in the range probably of 0% to 2%.

Okay, great. Thank you.

Our next question comes from the line of Joanna Gajek. with Bank of America, please go ahead.

Hi, good morning. Thank you. So hi, good morning. Thank you for taking that question. So I guess first the follow up when it comes to the episodic. So, you know, you said you expect that sort of mission to stabilize going forward since the mix is, you know, some of the peers. But so, you know, when I look at the payer mix, you know, in terms of the revenues, I understand the mix, you're shifting and growing the MA that you did not have, but then still the Medicare revenues is down 14% for the year and I guess 16% in this quarter year-over-year and down 7% sequentially. And when I look at the peers, they show either much smaller declines or even some show growth year-over-year. So I guess the question is, why and how that is losing market share?

joanne i don't think we're losing market share again i think it's part of this medicare eligible is choosing to enroll in medicare advantage and if you go back in history as you well know about this company is historically this company did not pursue medicare advantage and again we made that shift over the last 12 to 18 months to pursue that business whereas the peer group's been doing it over six to eight years so their you know, drop in the traditional Medicare wasn't like the inhabit cliff, as I referred to it over the past year. So I think that's what you're seeing when you try to compare it to peers. And what we're saying now is that we're not saying that, you know, we're going to suddenly start increasing traditional Medicare in 2024. Again, there has been a market shift and it continues to more Medicare eligible choosing Medicare Advantage. What we're saying is that we think that we're starting to get in a path where we're not on that cliff anymore and it's starting to stabilize more like the industry.

Okay.

And I guess another follow-up, or maybe that's a new topic, but related to this payer mix, situation here when I look at the average revenue per visit for the non-episodic visits right versus the revenue per visit for the episodic portion which that includes obviously Medicare and MA but still that average is like 43% below so like the non-episodic average 43% below the average for the episodic volumes So how should you think about that metric? It sounds like maybe you're going to change some disclosures and we will be able to kind of clearly see Medicare and then some other episodic separately. That's what you're trying to do to kind of give us more visibility. But I'm still surprised that that average is still that much lower. So I guess, you know, how should we think about this going forward?

Yes, so I think one thing is part of the numbers you're seeing, of course, after revenue reserves, and those can sometimes cause noise, as you're well aware, in any quarter and for the year as well, especially given the adjustment we had to make in the fourth quarter of 2022 and then throughout 2023 as we enhance those controls and updated our reserve methodology. Yes, going forward, as Barb mentioned, especially given the fact that we now have this national agreement that is an advanced episodic model. When we start reporting Q1 later this year, instead of just getting episodic admissions and non-episodic admissions and information that way, episodic will be broken out between traditional Medicare and then everything else that's episodic. And we believe that's important, again, primarily being driven by this new national agreement.

And if I may squeeze in just on that national agreement, any way to help us quantify like incremental, I guess, revenue or volumes from that contract? It sounds like some of these markets you already have been serving. So you kind of keep the volumes, but the rate is higher, but then it sounds like you also added more markets. So kind of any way to help us give us some size of that incremental? Thank you.

Sure, so we did not aggressively pursue that volume in the past. I would say when we look back in 23, it was about 5% of our admissions historically. We do have coverage throughout the country, and so that is certainly going to give us better access to those members. You know, one thing that we've consistently said in our payer innovation contracting is that, you know, we were looking for rates that were, you know, much improved over the historic contracts. And so, this does align with the focus of the payer innovation team from a rate perspective.

Thank you.

Our next question comes from the line of AJ Rice with UBS. Please go ahead.

Hi, good morning. This is for AJ. Good morning. So, good morning. So in Q4, the company got to around 25% of visits as a percentage of total non-episodic visits in these payer innovation contracts. I mean, just run reading that, there will be a degree of a tailwind for next year. Does the company expect the fast pace to continue in 24 as well? Just trying to size the momentum of getting more visits into these higher paying contracts.

I think it's a reason why it's going to be important for us to give you information as it relates to episodic fee-for-service and payer innovation and non-episodic, because as we are having more success getting these payers signing with episodic, you may see some moderation in this non-episodic move, mainly because our addressable market is becoming now greater in where we have our episodic contracts. So I think, again, as Chrissy mentioned, that's why it's going to be important for us to give more detail on those various groups into 2024.

Got it. I guess a follow-up on that would be in these MA episodic contracts versus the non-episodic contracts, how much of a rate increase would that create for the company in 2024, I guess?

Historically, we have talked about a 0% to 10% rate differential to Medicare fee-for-service for our episodic MA contract. And we talked about kind of a 25% to 30% discount for the non-episodic MA contract compared to Medicare fee-for-service. Well, now this is part of that shift, given that we now have a national advanced episodic model contract. we no longer can talk really about episodic versus non-episodic. It's just got to be what's in this payer innovation contract as we refer to them. So I think the answer to your question is that all of our contracts currently have somewhere between a zero and about a 25% discount to Medicare fee for service.

Got it. Thanks. Maybe one more just to clarify. On the hospice side, there seems to be a estimated recoverability of net service revenue in the quarter, is that a one-time benefit? And how much of a revenue and EBITDA effect did that have? Thanks.

Yeah, I think that that is more about Q4 of 2022. You may recall that there was a rather significant adjustment made to our revenue reserves in the fourth quarter of 2022. For the total company, it was about 12 million, and 7 million of that went to the hospice segment. So that's the noise that we're talking about. In the slide, it's talking about a year-over-year change for the segment. And so that estimate and the change in recoverability really relates more to Q4 2022 and the entry we made then more so than anything that happened in Q4 of 2023. Great. Thanks a lot.

Our next question comes from the line of Brian Langston with TD Cowan. Please go ahead.

Hi, thank you. Just two quick ones for me. Maybe I'll try the payer innovation question a little differently. Obviously, it's jumped from, I think, 5% to 25% a year, which is pretty good success. Maybe just more broadly, what do we think about that percentage maybe into 24% into 25% given maybe where your staggered contracts are up for renewal, or you can go for maybe outside of normal renewal schedules. And then can you maybe give us a little sense? I mean, you've already had two months of experience now this year. Just maybe more generally where the mix shift has moved from fee-for-service to MA between 4Q and 1Q, just to maybe give us a little help with the modeling. Thanks.

Sure. Well, as it relates to that, we do think there continues to be opportunity to move those non-episodic visits in the payer innovation contracts. So as you mentioned, going from 5% to 25% we felt was really good improvement this year. The piece that's the hardest to determine what 24 looks like is really because of the success in getting the episodic contracts and in particularly a new national episodic. So as you think of the move, it may be the move into payer innovation contracts not necessarily the non-episodic into non-episodic payer innovation contracts, if that helps. So that's why it's a little bit hard to talk about that percentage because historically we've been focused on moving from kind of our really low paying, which were all non-episodic in the past, and improving that, whereas now we're going to have a much more broader market to go after, including a fair amount of episodic contract patients.

Got it.

And then I don't know if you can give us a sense on just the first two months of this year, just in terms of the mix. It sounds like you're obviously expecting that to moderate, and I would expect that too. But any sense on where that's actually gone into the first part of the first quarter?

I mean, I think we'll obviously have a lot more of that when we report quarter one because, again, breaking this out in different buckets I think is going to be helpful. I would say as it relates to quarter one from a financial perspective, that does take time because you still have – a fair number of patients that are on your census that started sometime within quarter four, many that could still be in maybe what would have been like our least desirable contracts. And so, it takes time for those patients to be discharged and replace those with the higher-paying contracts.

Okay.

Thank you very much. Our next question comes from the line of Jason Casorla with Citigroup. Please go ahead.

Great. Thanks for the follow-up. I just wanted to hone in on capital deployment priorities, more specifically around your leverage. I guess, how should we be thinking about the uses of your free cash flow for 24? Do you anticipate using the bulk of it for debt or pay down of your revolver? Or are you anticipating leverage would just naturally improve as EBITDA grows, just any color around priorities and debt repayment?

Yes, so we are more focused on deleveraging. Our free cash flow will go towards $20 million of required amortization on our term loan A. We also have the de novo strategy, which is probably $2.5 to $3.5 million as disclosed in our supplemental slides. But again, we think that's ample to do that. Anything above that would likely go towards revolver paydowns You know, and that's kind of the easy way to think about it, Jason, is to think, you know, assume 50% free cash flow conversion.

You've got $20 million of required amortization on the term loan, that money for the de novo spend as well, and then everything else is a potential revolver pay down.

Okay, great. Thanks, Rebecca.

I'll follow up with one more just on the de novo side. The eight that you will put up in 23, just curious, on how the ramp has progressed across those locations so far. And, you know, in the past, you've mentioned a focus on hospice build out and just in context of building your co-location strategy. 2023, the de novos are about evenly split between home health and hospice. I guess for the 10 that you're planning on for 24, how should we think about those locations? Again, are they evenly split between home health and hospice or just any color that would be helpful on the de novo front?

Yeah, they continue to be geared a little bit more towards hospice with our strategy being opening up hospice wherever we have an existing home health. So they're geared a little bit more towards hospice. You know, the de novo that we opened up in 2022 and 2023 are doing well. You know, some are running at plans, some are running ahead of plans. And so in 2024, I think it's fair to say that the investment that we continue to make in the 10s We'll be offset by the earnings of those that we opened up in 2022 and 2023.

Okay.

Thank you.

Our next question comes from the line of Joanna Gajek with Bank of America. Please go ahead.

Hi. Thank you for taking a follow-up here. So I guess I have two. One is on this payer technology. Sources slide 31, where you have the fourth quarter hospice and the managed care is 6.5%. So can you explain why there's such a big number? Because it also talks about, yes, an increase in the non-medical patient revenue, but also, again, talks about this... recoverability or estimated recoverability of the revenue. So can you help us understand like what is the 6.5% really represents?

Yes. So it represents exactly what it says. It is managed care in our hospice, some of the VBID contracts and other contracts that were in 2023. You'll notice that the 2022 column is blank. It's zero. And again, that's because a lot of that reserve for hospice that we made in the fourth quarter of 2022 went to that line item.

Okay. Thank you. And my other question, I guess, when it comes to regulations, so what do you expect to see in 2025 home health proposal that is going to be coming out, I guess, soon, a couple of months, but any initial thoughts around uh you know productivity adjustments and recruitment and also i guess first we're gonna get a hospice proposal um for 2025 so so any ex any thing around what do you expect to see in that one thank you

Sure. I would say for home health, I mean, I think they already kind of signaled last year that they would go after the other half of the adjustment that they ended up cutting in half last year. So, I think that we anticipate that being part of the proposed rule. I think it's a good question on the temporaries. I don't know at this point. As you know, in the previous rules, it hasn't been discussed or mentioned yet on how, if, and when what that would look like. I think that is a big question mark on whether that will appear in the proposed for 25 or if that's something that will happen after they finish the permanent adjustment. So I think for sure we would expect to see something about the permanent continuing, but a big question mark, I think, on the temporary. And then on hospice, at this point, don't really anticipate there's going to be anything different as far as their proposed rule.

Thank you.

There are no further questions at this time. I would now like to turn the call over to Chrissy Carlisle for closing remarks.

Thank you, Operator. And thanks to each of you for joining today's call. If you have additional questions, please email InvestorRelations at ehab.com.

This concludes today's call. You may now disconnect.